## CONSERVE Checklist - CLARITY 2.0 Trial

Use CONSERVE-CONSORT for completed trial reports and CONSERVE-SPIRIT for trial protocols.

CONSI	ERVE-CONSORT Extension: 1	3 <sup>th</sup> August 2024			
Item	Item Title	Description	Page No.		
l.	Extenuating Circumstances	Describe the circumstances and how they constitute extenuating circumstances.			4, 6
II.	Important Modifications	a. Describe I	4,5,6		
			d mitigating strategies, and implications for the	5,6	
		c. Provide a	5, Figure 1		
III.	Responsible Parties	State who planr modifications.	anned, reviewed and approved the s.		4
IV.	Interim data	If modifications how the interim they were exam individuals revie treatment alloca	5		
CONSORT Number and Item		For each row, if important modifications occurred check "direct impact" and/or "mitigating strategy" and describe the changes in the trial manuscript or supplement. Check "no change" for items that are unaffected in the extenuating circumstance.			Page No.
		No Change	Impact*	Mitigating Strategy**	
1	Title and abstract	Х			
2	Introduction	Х			
3	Methods: Trial Design	Х			
4	Methods: Participants		Х	Х	4,5,6
5	Methods: Interventions	Х			
6	Methods: Outcomes	Х			
7	Methods: Sample Size		Х	Х	4,5,6

8-10	Methods: Randomisation	Х		
11	Methods: Blinding	Х		
12	Methods: Statistical methods	Х		
13	Results: Participant flow	Х		
14	Results: Recruitment		Х	5,6
15	Results: Baseline data	Х		
16	Results: Numbers analysed		Х	5,6
	Results: Outcomes and estimation		Х	6
18	Results: Ancillary analyses	Χ		
19	Results: Harms	Х		
20	Discussion: Limitations		Х	6,7
21	Discussion: Generalisability		Х	7
	Other information: Registration	Х		
24	Other information: Protocol	Х		
25	Other information: Funding	Х		

<sup>\*</sup>Aspects of the trial that are directly affected or changed by the extenuating circumstance and are not under the control of investigators, sponsor or funder.

\*\*Aspects of the trial that are modified by the study investigators, sponsor or funder to respond to the

<sup>^^</sup>Aspects of the trial that are modified by the study investigators, sponsor or funder to respond to the extenuating circumstance or manage the direct impacts on the trial.